Investor Relations
Abcam IR Home
Share price & chart
Reports & accounts / Financial Calendar
Regulatory news (RNS)
Contacts & advisors
Governance
CSR statement
Directors
Major shareholders
Other Documents
The Abcam story
About research antibodies
Abcam company news
Main Abcam website

REG-ABCAM Plc Director/PDMR Shareholding

http://pdf.reuters.com/Regnews/regnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20091103:RnsC8703B
                                                                                                                       .
RNS Number : 8703B  
  
ABCAM Plc  
  
03 November 2009  
  
Abcam plc ("Abcam" or "the Company")   
  
Director Dealings   
  
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that 
markets antibodies via its own online catalogue, announces that it was notified 
on 2 November 2009 that Tim Dye, a non-executive director of the Company, bought 
2,500 ordinary shares of 1 pence each in the Company on 2 November 2009 at a 
price of 941p per ordinary share. Following this transaction Mr Dye has an 
interest in 2,500 ordinary shares of 1 pence each in the Company.  
  
 
  Abcam                                              + 44 (0) 1223 696000   
  Jonathan Milner, Chief Executive Officer                                  
  Jeffrey Iliffe, Chief Financial Officer                                   
                                                                            
  Numis Securities                                   + 44 (0) 20 7260 1000  
  Michael Meade / Nick Westlake, Nominated Adviser                          
  James Black, Corporate Broking                                            
                                                                            
  Buchanan Communications                            + 44 (0) 20 7466 5000  
  Mark Court / Mary-Jane Johnson / Stasa Filiplic                           
  
  
Notes for editors:   
  
About Abcam plc   
  
Abcam is a producer and distributor of research-grade antibodies headquartered 
in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, 
Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and 
trades under the ticker symbol ABC. The Company produces and distributes its own 
and third-party produced antibodies to academic and commercial users throughout 
the world. Product ordering is available through the Company's website 
www.abcam.com, where customers are also able to access up-to-date and detailed 
technical product data sheets. All the antibodies are sold under the Abcam brand 
name and the Company's vision is to build the world's largest online resource of 
high-quality and commercially viable antibodies. Abcam now has an online 
catalogue of over 56,000 products, most of which are antibodies, from over 250 
suppliers and employs 243 staff in its three operating companies.   
  
 
This information is provided by RNS  
  
The company news service from the London Stock Exchange  
  
  END  
  
RDSXXLFBKFBXFBZ  
  

---

back to RNS news